The FDA is experiencing a significant morale and staffing crisis following major personnel departures in April and ongoing talent losses. This exodus threatens the agency’s capacity to maintain regulatory quality and timeliness for drugs, devices, and inspections, compounding challenges caused by politicization and leadership distrust. The situation raises concerns over potential slowdowns and disruptions in approvals critical to the biotech industry.